Table 1 Association of serum levels of 24 fatty acids with odds of prostate cancer case status stratified by population group

From: Circulating trans fatty acids are associated with prostate cancer in Ghanaian and American men

  

All (n = 2934)

Ghanaian (n = 1243)

African American (n = 788)

European American (n = 903)

Fatty acid

Fatty acid class

Multivariablea

OR (95% CI)

P-valueb

Multivariablec

OR (95% CI)

P-valueb

Multivariablec

OR (95% CI)

P-valueb

Multivariablec

OR (95% CI)

P-valueb

Eicosenoic

cis -Monounsaturated

1.00 (0.93, 1.08)

0.930

1.08 (0.89, 1.30)

0.422

0.82 (0.71, 0.96)

0.015

1.07 (0.96, 1.20)

0.235

Nervonic

cis -Monounsaturated

1.18 (1.09, 1.28)

1.70E-05

1.19 (1.06, 1.34)

0.004

1.18 (0.98, 1.43)

0.087

1.09 (0.91, 1.30)

0.338

Oleic

cis -Monounsaturated

1.17 (1.08, 1.26)

8.70E-04

1.36 (1.15, 1.61)

3.40E-03

0.97 (0.84, 1.11)

0.626

1.17 (1.04, 1.33)

0.012

Palmitoleic

cis -Monounsaturated

1.07 (0.99, 1.15)

0.087

0.87 (0.74, 1.02)

0.092

1.07 (0.92, 1.24)

0.384

1.24 (1.07, 1.43)

0.004

alpha-Linolenic (ALA)

Omega-3

1.09 (0.99, 1.19)

0.074

1.75 (1.05, 2.90)

0.031

0.92 (0.80, 1.06)

0.247

1.10 (0.96, 1.25)

0.179

Docosahexaenoic (DHA)

Omega-3

0.51 (0.45, 0.56)

1.40E-33

0.37 (0.31, 0.44)

4.60E-25

0.84 (0.59, 1.19)

0.323

1.01 (0.77, 1.30)

0.969

Docosapentaenoic - n3 (DPA)

Omega-3

0.73 (0.67, 0.79)

5.00E-12

0.53 (0.46, 0.61)

2.30E-15

0.93 (0.77, 1.11)

0.412

1.16 (0.99, 1.36)

0.066

Eicosapentaenoic (EPA)

Omega-3

0.62 (0.56, 0.68)

1.60E-17

0.56 (0.48, 0.64)

9.30E-11

0.68 (0.48, 0.96)

0.031

0.95 (0.77, 1.18)

0.662

Arachidonic (AA)

Omega-6

0.98 (0.89, 1.07)

0.586

0.56 (0.46, 0.70)

6.00E-06

1.03 (0.87, 1.21)

0.771

1.11 (0.95, 1.31)

0.186

Dihomo-g-linolenic (DGLA)

Omega-6

1.18 (1.09, 1.28)

1.20E-04

0.88 (0.75, 1.03)

0.117

1.15 (0.99, 1.34)

0.064

1.30 (1.13, 1.50)

2.30E-04

Docosapentaenoic - n6

Omega-6

1.09 (1.01, 1.18)

0.025

0.57 (0.46, 0.71)

6.80E-05

1.19 (1.04, 1.35)

0.009

1.25 (1.08, 1.46)

0.004

Docosatetraenoic

Omega-6

1.25 (1.14, 1.37)

1.30E-04

0.84 (0.63, 1.11)

0.210

1.14 (0.99, 1.32)

0.066

1.33 (1.13, 1.56)

0.001

Eicosadienoic

Omega-6

1.09 (1.00, 1.18)

0.054

0.81 (0.65, 1.00)

0.052

0.98 (0.87, 1.11)

0.742

1.27 (1.09, 1.47)

0.002

gamma-Linolenic (GLA)

Omega-6

1.13 (1.04, 1.23)

0.005

0.80 (0.65, 0.97)

0.027

1.07 (0.92, 1.24)

0.375

1.22 (1.07, 1.39)

0.003

Linoleic (LA)

Omega-6

1.03 (0.94, 1.12)

0.533

0.77 (0.63, 0.93)

0.009

0.88 (0.75, 1.03)

0.103

1.12 (0.98, 1.29)

0.085

Arachidic

Saturated

1.09 (1.01, 1.18)

0.033

1.35 (1.11, 1.64)

0.002

0.80 (0.67, 0.95)

0.013

1.08 (0.96, 1.23)

0.209

Behenic

Saturated

1.08 (1.01, 1.17)

0.033

1.22 (1.06, 1.41)

0.006

0.88 (0.77, 1.01)

0.078

1.04 (0.91, 1.18)

0.564

Lignoceric

Saturated

1.02 (0.95, 1.10)

0.596

1.05 (0.92, 1.19)

0.444

0.93 (0.80, 1.08)

0.326

0.99 (0.86, 1.14)

0.865

Myristic

Saturated

0.98 (0.91, 1.06)

0.675

0.80 (0.66, 0.97)

0.021

0.96 (0.84, 1.10)

0.559

1.17 (1.03, 1.34)

0.018

Palmitic

Saturated

1.22 (1.13, 1.33)

3.50E-05

1.44 (1.22, 1.70)

9.90E-04

1.02 (0.89, 1.18)

0.739

1.20 (1.05, 1.37)

0.006

Stearic

Saturated

1.30 (1.20, 1.41)

7.10E-08

1.59 (1.34, 1.89)

5.90E-06

1.04 (0.90, 1.19)

0.599

1.21 (1.06, 1.38)

0.004

Elaidic

trans -Monounsaturated

1.52 (1.36, 1.70)

1.38E-04

12.29 (4.77, 31.60)

1.38E-04

1.41 (1.19, 1.68)

1.73E-04

1.39 (1.21, 1.60)

2.92E-04

Palmitelaidic

trans -Monounsaturated

1.35 (1.23, 1.47)

7.00E-10

1.69 (1.36, 2.10)

1.20E-04

1.31 (1.11, 1.55)

0.001

1.24 (1.10, 1.40)

3.50E-04

Linoelaidic

trans -Polyunsaturated

1.49 (1.35, 1.66)

1.19E-04

2.79 (1.91, 4.07)

1.19E-04

1.31 (1.10, 1.56)

0.003

1.34 (1.18, 1.53)

4.90E-06

  1. aLogistic regression adjusted for age at recruitment and population group. ORs represent an increase in estimated prostate cancer risk per one standard deviation increase for each fatty acid.
  2. bBonferroni adjusted threshold for significance is P = 0.0021 to account for multiple testing.
  3. cLogistic regression adjusted for age at recruitment. ORs represent an increase in the estimated odds of prostate cancer per one standard deviation increase for each fatty acid.
  4. OR Odds Ratio, CI Confidence Interval.
Back to article page